POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Blood cancer drug bomedemstat gets Long-Term safety review in 400 patients
Disease control Recruiting nowThis study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who are already taking the drug bomedemstat and doing well. It aims to collect long-term safety information and see how well the drug continues to work. About 400 participants wi…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
New drug trial hopes to tame rare blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug called PRT12396 in about 100 people with two rare blood cancers: polycythemia vera and myelofibrosis. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug helps control the di…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New hope for myelofibrosis: tasquinimod trial opens
Disease control Recruiting nowThis study tests a drug called tasquinimod, given alone or with another drug (ruxolitinib), to see if it can help control myelofibrosis—a serious bone marrow disorder. About 33 adults with certain types of myelofibrosis who have not responded to or cannot take standard treatments…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC